CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD.

China National Accord Medicines Corporation Ltd.

000028

CNE0000009N6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
34.95 ^CNY	+2.52%		+2.79%	+20.56%

Apr. 08	China National Accord Medicines Corporation Ltd. Proposes Final Cash Dividend for the Year 2023	CI
Apr. 07	China National Accord Medicines Corporation Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

China National Accord Medicines Corporation Ltd.(SZSE:200028) added to S&P Global BMI Index

September 19, 2016 at 12:00 am EDT

Latest news about China National Accord Medicines Corporation Ltd.

China National Accord Medicines Corporation Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 08	CI
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 07	CI
China National Accord Medicines' Profit Slides 4% in Q3	23-10-26	MT
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Correction: Sinopharm Subsidiary Sinopharm Accord Logs Over 29% Jump in H1 Net Profit	23-08-08	MT
Sinopharm Group Logs Over 29% Jump in H1 Net Profit	23-08-08	MT
China National Accord Medicines Approves Final Cash Dividend for 2022	23-05-12	CI
Energy International Investments to Raise HK$150 Million from Share Issue to Affiliate	23-05-01	MT
Sinopharm Accord Logs 44% Rise in Q1 Profit	23-04-25	MT
Sinopharm Accord's Q1 Profit Surges 43.5%	23-04-17	MT
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-17	CI
China National Accord Medicines Corporation Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-13	CI
Pfizer signs strategic cooperation pact with China's Sinopharm	23-04-13	RE
Sinopharm Accord's 2022 Attributable Profit Up 11%; Shares Jump 5%	23-04-13	MT
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Merck's COVID treatment expected to launch in China on Friday	23-01-11	RE
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
China National Accord Medicines Corporation Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022	22-06-13	CI
China National Accord Medicines Corporation Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
China National Accord Medicines Corporation Ltd. Approves Final Cash Dividend for the Year 2021	22-04-25	CI
Nomura Adjusts China National Accord Medicines' Price Target to 49.1 Yuan From 54.5 Yuan, Keeps at Buy	22-04-04	MT
China National Accord Medicines Corporation Ltd. Proposes Final Cash Dividend for the Year 2021	22-03-30	CI

Chart China National Accord Medicines Corporation Ltd.

Duration

Period

Chart China National Accord Medicines Corporation Ltd.

More charts

China National Accord Medicines Corporation Ltd. is a China-based company principally engaged in the pharmaceutical wholesaling, retailing and manufacturing businesses. The Company's main products include antibiotic preparations, power injections, antibiotic Active Pharmaceutical Ingredients (APIs), respiratory system drugs and cardiovascular and cerebrovascular system drugs, among others. The Company is also involved in the provision of logistics and storage services, leasing services and training services, among others. The Company distributes its products mainly in domestic market.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for China National Accord Medicines Corporation Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

34.95 CNY

Average target price

36.79 CNY

Spread / Average Target

+5.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD.	+20.56%	2.42B
MCKESSON CORPORATION	+15.65%	69.91B
CARDINAL HEALTH, INC.	+2.72%	25.14B
SINOPHARM GROUP CO. LTD.	+4.89%	8.32B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.10%	8.07B
HUADONG MEDICINE CO., LTD	-21.85%	7.97B
H. LUNDBECK A/S	+0.73%	4.56B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.40%	4.31B
EBOS GROUP LIMITED	-0.14%	3.99B
GALENICA AG	-2.34%	3.87B

Pharmaceuticals Wholesale